Postmenopausal Vaginal Atrophy Epidemiology Forecast 2025-2034

Vaginal atrophy is a common concern among postmenopausal women, with around 40% to 54% of such individuals reporting bothersome symptoms. With menopause causing a dramatic reduction in estrogen production, the postmenopausal population often experiences vaginal dryness, pain during intercourse, and urinary urgency, among others.

Postmenopausal Vaginal Atrophy Epidemiology Forecast Report Coverage

The “Postmenopausal Vaginal Atrophy Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of postmenopausal vaginal atrophy. It projects the future incidence and prevalence rates of postmenopausal vaginal atrophy across various populations. The study covers age and type as major determinants of the postmenopausal vaginal atrophy-affected population. The report highlights patterns in the prevalence of postmenopausal vaginal atrophy over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of postmenopausal vaginal atrophy in the 8 major markets.

Regions Covered

• The United States
• EU-4 (Germany, France, Italy, Spain) and the United Kingdom
• Japan
• India

Postmenopausal Vaginal Atrophy: Disease Overview

Vaginal atrophy (genitourinary syndrome of menopause or atrophic vaginitis) is a prevalent condition affecting women transitioning to menopause. It is characterized by changes in the lining of the vagina, where it becomes drier and thinner, as a result of lack of estrogen. Common symptoms include itching, spotting, burning, frequent urination, pain during sex, and urinary tract infections. Various studies reveal that nearly half of the women who enter menopause show symptoms and signs of vaginal atrophy, with vaginal dryness often the first indication of the condition.

Postmenopausal Vaginal Atrophy: Treatment Overview

Treatment of vaginal atrophy in postmenopausal women focuses on managing symptoms, reversing or reducing the physiologic changes, and improving the patient’s quality of life. Estrogen therapy and dehydroepiandrosterone (DHEA) are the hormonal treatment options available for vaginal atrophy. Topical vaginal estrogen, in the form of a vaginal pill, ring, or cream, also helps in treating the symptoms without affecting the levels of estrogen in the bloodstream.

Epidemiology

The postmenopausal vaginal atrophy epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for postmenopausal vaginal atrophy by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for postmenopausal vaginal atrophy and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• Around 15% of women are reported to experience vaginal atrophy symptoms before menopause whereas 40% to 54% of postmenopausal women report bothersome symptoms caused by vaginal atrophy.
• As per an article published in Harvard Health Publishing (2019), nearly 50% of women develop symptoms associated with vaginal atrophy within a few years post-menopause.
• Studies reveal that 70% of women experiencing signs and symptoms of vaginal atrophy do not discuss their health issues with healthcare professionals. It is also estimated that less than 25% of the women suffering from vaginal atrophy receive appropriate medical care.
• According to a review article published in the Journal of South Asian Federation of Menopause Societies (2017), symptoms of urogenital atrophy are experienced by almost half of all postmenopausal women, with vaginal atrophy becoming clinically apparent post 4 to 5 years after the transition to menopause.

Country-wise Postmenopausal Vaginal Atrophy Epidemiology

The postmenopausal vaginal atrophy epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of postmenopausal vaginal atrophy differs between countries owing to factors such as socioeconomic status, and access to gynecological care, among others. Cultural attitudes also influence how openly women discuss and seek treatment for vaginal atrophy, which subsequently impacts the prevalence data in a region. For instance, in the United Kingdom, there are approximately 13 million individuals who are currently peri or menopausal. However, many women hesitate to discuss issues like vaginal atrophy with healthcare professionals.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of postmenopausal vaginal atrophy based on several factors.
• Postmenopausal Vaginal Atrophy Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India)
• The report helps to identify the patient population, and the unmet needs of postmenopausal vaginal atrophy are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of postmenopausal vaginal atrophy epidemiology in the 8 major markets?
• What will be the total number of patients with postmenopausal vaginal atrophy across the 8 major markets during the forecast period?
• What was the country-wise prevalence of postmenopausal vaginal atrophy in the 8 major markets in the historical period?
• Which country will have the highest number of postmenopausal vaginal atrophy patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of postmenopausal vaginal atrophy during the forecast period of 2025-2034?
• What are the currently available treatments for postmenopausal vaginal atrophy?
• What are the disease risks, signs, symptoms, and unmet needs of postmenopausal vaginal atrophy?

This product will be delivered within 3-5 business days.